PharmAust ready to trial monepantel on humans to fight motor neurone disease
PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues.
Monepantel is a potent small molecule drug that has been shown to modulate the mTOR pathway, which plays a pivotal role in driving many cancers.